Researchers Study Nasal Administration of Bionor Pharma's Therapeutic HIV Vaccine Vacc-4x Combined With Eurocine Vaccines' Endocine(TM) in Fully Enrolled Trial; New Treatment Option Would Offer Easier Treatment Access for HIV Patients Globally
January 04, 2012 08:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jan 4, 2012) -
News Summary
Bionor Pharma's Vacc-4x is an investigational therapeutic HIV vaccine that has already shown in a...
Bionor Pharma's Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by All Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study
November 22, 2011 08:00 ET
|
Bionor Pharma
ARLINGTON, VA--(Marketwire - Nov 22, 2011) -
Summary of Findings
Bionor's Vacc-Flu could be "Universal," meaning that it could work on seasonal flu and also on...
Results From Phase IIB Placebo Controlled Study of Bionor Pharma's Vacc-4x Show Excellent Safety Profile, Statistically Significant Viral Load Reduction in Patients With HIV Who Suspend Antiretroviral Therapy
September 14, 2011 02:30 ET
|
BionorPharma
BANGKOK, THAILAND--(Marketwire - Sep 14, 2011) - Results from the furthest advanced study of a therapeutic vaccine candidate to treat people living with HIV/AIDS were announced at a news conference...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
August 25, 2011 08:00 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...
Further Analysis of Vacc-4x Phase IIb Study Shows a Statistically Significant Reduction in Viral Load Over Placebo -- Previous Decision to Put Vacc-4x on Hold Has Been Reversed
November 18, 2010 09:05 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - November 18, 2010) - After further analyses of the international, randomized, double-blind, placebo-controlled multi-center phase IIb study of Bionor Pharma's (OSLO:...
Henrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
August 30, 2010 09:14 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - August 30, 2010) - Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1...
Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine
August 30, 2010 09:13 ET
|
BionorPharma
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -
Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7...
Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria
July 22, 2010 06:59 ET
|
BionorPharma
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted...
UPDATE: NutriPharma ASA and Subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting
May 27, 2010 10:48 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - May 27, 2010) - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known...
New Path to Therapeutic HIV Vaccine Discovered by Studying Immunologic Profile of Rare HIV Controllers
March 17, 2010 11:30 ET
|
Bionor Immuno
OSLO, NORWAY--(Marketwire - March 17, 2010) - Based on encouraging results from pre-clinical research, Bionor Immuno AS today announced intentions to take the therapeutic and potentially...